DHODH inhibitors are currently considered a promising option for differentiation therapy of AML2 and, although clinical application of brequinar is limited due to severe adverse reactions, several novel inhibitors of DHODH are developed that exerted the similar effects on AML differentiation, including BAY 24023432 and ASLAN00322. Here, DHODH is linked to acute myeloid leukemia.